Future Cardiology – Clopidogrel is an ideal target for pharmacogenetic intervention for several reasons. First, there is a strong association between genotype, in this case CYP2C19 genotype, and clopidogrel effectiveness [1]. Second, the consequences of reduced clopidogrel effectiveness, namely adverse cardiovascular events, can be life threatening and costly. Because of these reasons, an increasing number of institutions have implemented CYP2C19 genotyping to predict clopidogrel response into clinical practice.
